{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:03:42Z","timestamp":1772121822158,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"Supplement_L","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Coexistence of atrial fibrillation and ischaemic heart disease is very common and patients affected by these conditions are exposed to both a high ischaemic and haemorrhagic risk. The choice of an appropriate combination of anticoagulant therapy with single or dual antiplatelet treatment is indeed one of the most relevant and contemporary challenges in clinical practice. Several studies and meta-analyses pointed out that 1 year after an acute coronary syndrome or percutaneous revascularization, the use of the sole anticoagulant therapy is not associated with increased risk of major cardiovascular events, whereas there is a substantial reduction of clinical significant bleeding events, as compared to patients treated also with antiplatelet medications. However, there are no clear-cut data regarding the possibility to implement this strategy in each patient, regardless the cardiovascular risk class. Furthermore, for patients requiring a combined anticoagulant and antiplatelet treatment, the available data seem to favour an association of direct anticoagulant and inhibitors of P2Y12, rather than regimens including aspirin. These data are derived mainly from observational studies, with all their limitations. The use of aspirin could be beneficial in patients with significant comorbidities, such as diabetes mellitus, or with severe peripheral atherosclerotic disease, involving the carotids and other large arteries.<\/jats:p>","DOI":"10.1093\/eurheartj\/suaa159","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T23:54:31Z","timestamp":1605743671000},"page":"L166-L169","source":"Crossref","is-referenced-by-count":8,"title":["Atrial fibrillation and ischaemic heart disease: should we use acetylsalicylic acid beside anticoagulants?"],"prefix":"10.1093","volume":"22","author":[{"given":"Massimo","family":"Volpe","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy"},{"name":"IRCCS Neuromed, Pozzilli, Isernia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Gallo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"2020111813470070800_suaa159-B1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2019.02.080","article-title":"Antithrombotics: from aspirin to DOACs in coronary artery disease and atrial fibrillation","volume":"74","author":"Verheugt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2020111813470070800_suaa159-B2","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"2020111813470070800_suaa159-B3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"2020111813470070800_suaa159-B4","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2020111813470070800_suaa159-B5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","article-title":"2018 Joint European Consensus Document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)","volume":"21","author":"Lip","year":"2019","journal-title":"Europace"},{"key":"2020111813470070800_suaa159-B6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.amjcard.2019.05.072","article-title":"Meta-analysis of oral anticoagulant monotherapy as an antithrombotic strategy in patients with stable coronary artery disease and nonvalvular atrial fibrillation","volume":"124","author":"Lee","year":"2019","journal-title":"Am J Cardiol"},{"key":"2020111813470070800_suaa159-B7","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","article-title":"Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation","volume":"139","author":"Matsumura-Nakano","year":"2019","journal-title":"Circulation"},{"key":"2020111813470070800_suaa159-B8","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"key":"2020111813470070800_suaa159-B9","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJMe1910560","article-title":"Antithrombotic therapy in atrial fibrillation and coronary artery disease","volume":"381","author":"Becker","year":"2019","journal-title":"N Engl J Med"},{"key":"2020111813470070800_suaa159-B10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"2020111813470070800_suaa159-B11","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"2020111813470070800_suaa159-B12","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"2020111813470070800_suaa159-B13","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2020111813470070800_suaa159-B14","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/eurheartj\/ehy162","article-title":"Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials","volume":"39","author":"Golwala","year":"2018","journal-title":"Eur Heart J"},{"key":"2020111813470070800_suaa159-B15","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","article-title":"Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials","volume":"4","author":"Lopes","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2020111813470070800_suaa159-B16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCULATIONAHA.118.037440","article-title":"Aspirin on top of anticoagulation in patients with concomitant stable coronary artery disease and atrial fibrillation no clear answer yet","volume":"139","author":"Lemesle","year":"2019","journal-title":"Circulation"},{"key":"2020111813470070800_suaa159-B17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2020111813470070800_suaa159-B18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(18)31307-2","article-title":"Weight-adjusted aspirin for cardiovascular prevention","volume":"392","author":"Theken","year":"2018","journal-title":"Lancet"},{"key":"2020111813470070800_suaa159-B19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet"},{"key":"2020111813470070800_suaa159-B20","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/CIR.0000000000000182","article-title":"Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association","volume":"131","author":"Kulik","year":"2015","journal-title":"Circulation"},{"key":"2020111813470070800_suaa159-B21","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"2020111813470070800_suaa159-B22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40292-017-0213-4","article-title":"Aspirin and the primary prevention of cardiovascular diseases: an approach based on individualized, integrated estimation of risk","volume":"24","author":"Volpe","year":"2017","journal-title":"High Blood Press Cardiovasc Prev"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/22\/Supplement_L\/L166\/34386641\/suaa159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/22\/Supplement_L\/L166\/34386641\/suaa159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T23:54:36Z","timestamp":1605743676000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/22\/Supplement_L\/L166\/5989634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":22,"journal-issue":{"issue":"Supplement_L","published-online":{"date-parts":[[2020,11,18]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/suaa159","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,11,1]]}}}